These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 16126403)

  • 1. Tirofiban and emergency coronary surgery.
    Shanmugam G
    Eur J Cardiothorac Surg; 2005 Oct; 28(4):546-50. PubMed ID: 16126403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perioperative use of tirofiban hydrochloride (Aggrastat) does not increase surgical bleeding after emergency or urgent coronary artery bypass grafting.
    Bizzarri F; Scolletta S; Tucci E; Lucidi M; Davoli G; Toscano T; Neri E; Muzzi L; Frati G
    J Thorac Cardiovasc Surg; 2001 Dec; 122(6):1181-5. PubMed ID: 11726894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute profound thrombocytopenia after treatment with tirofiban and off-pump coronary artery bypass grafting.
    Beiras-Fernandez A; Kowert A; Jiru P; Weis M; Spannagl M; Reichart B; Schmoeckel M
    Ann Thorac Surg; 2009 Feb; 87(2):629-31. PubMed ID: 19161801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of glycoprotein IIb/IIIa inhibitors in urgent or emergency coronary artery bypass graft surgery.
    Cheng DK; Jackevicius CA; Seidelin P; Feindel C; Rouleau JL
    Can J Cardiol; 2004 Feb; 20(2):223-8. PubMed ID: 15010747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two distinct subgroups of tirofiban-induced thrombocytopenia exist due to drug dependent antibodies that cause platelet activation and increased ischaemic events.
    Dunkley S; Evans S; Gaudry L; Jepson N
    Platelets; 2005 Dec; 16(8):462-8. PubMed ID: 16287613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tirofiban optimizes platelet inhibition for immediate percutaneous coronary intervention in high-risk acute coronary syndromes.
    Ivandic BT; Kurz K; Keck F; Staritz P; Lehrke S; Katus HA; Giannitsis E
    Thromb Haemost; 2008 Oct; 100(4):648-54. PubMed ID: 18841288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitors of the platelet receptor glycoprotein IIb-IIIa and complications during percutaneous coronary revascularization. Management strategies for the cardiac surgeon.
    Dyke C; Bhatia D
    J Cardiovasc Surg (Torino); 1999 Aug; 40(4):505-16. PubMed ID: 10532207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet inhibition with tirofiban early during percutaneous coronary intervention: dosing revisited.
    Lakkis N; Lakiss N; Bobek J; Farmer J
    Catheter Cardiovasc Interv; 2002 Aug; 56(4):474-7. PubMed ID: 12124955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Controversies surrounding platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention and acute coronary syndromes.
    Harrington RA
    Semin Thromb Hemost; 2004 Dec; 30(6):639-47. PubMed ID: 15630670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Practical approach to the diagnosis and management of thrombocytopenia associated with tirofiban treatment.
    Mulot A; Moulin F; Fohlen-Walter A; Angioi M; Sghaier M; Carteaux JP; Lecompte T; de Maistre E
    Am J Hematol; 2004 Sep; 77(1):67-71. PubMed ID: 15307109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The emerging role of platelet glycoprotein IIb/IIIa inhibitors in managing high-risk patients with non-ST segment elevation acute coronary syndromes.
    Bolognese L
    Curr Med Res Opin; 2007 Jun; 23(6):1217-26. PubMed ID: 17559721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The in-vitro effect of tirofiban, glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets.
    Ciborowski M; Tomasiak M; Rusak T; Winnicka K; Dobrzycki S
    Blood Coagul Fibrinolysis; 2008 Sep; 19(6):557-67. PubMed ID: 18685439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heparin-induced thrombocytopenia and cardiopulmonary bypass: anticoagulation with unfractionated heparin and the GPIIb/IIIa inhibitor tirofiban and successful use of rFVIIa for post-protamine bleeding due to persistent platelet blockade.
    Durand M; Lecompte T; Hacquard M; Carteaux JP
    Eur J Cardiothorac Surg; 2008 Sep; 34(3):687-9. PubMed ID: 18579401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical benefits of adjunctive tirofiban therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Shen J; Zhang Q; Zhang RY; Zhang JS; Hu J; Yang ZK; Zheng AF; Zhang X; Shen WF
    Coron Artery Dis; 2008 Jun; 19(4):271-7. PubMed ID: 18480672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of tirofiban plus clopidogrel and aspirin on primary percutaneous coronary intervention via transradial approach in patients with acute myocardial infarction.
    Fu XH; Hao QQ; Jia XW; Fan WZ; Gu XS; Wu WL; Hao GZ; Li SQ; Jiang YF; Geng W
    Chin Med J (Engl); 2008 Mar; 121(6):522-7. PubMed ID: 18364139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycoprotein IIb-IIIa inhibitors in the emergency department for patients with non-ST-elevation acute coronary syndromes: principles and practices.
    Lefebvre CW; Hoekstra JW; Bonaca M; Giugliano R
    J Emerg Med; 2009 Feb; 36(2):162-70. PubMed ID: 18353601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vanishing platelets: rapid and extreme tirofiban-induced thrombocytopenia after percutaneous coronary intervention for acute myocardial infarction.
    Rahman N; Jafary FH
    Tex Heart Inst J; 2010; 37(1):109-12. PubMed ID: 20200641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current strategies with high-dose tirofiban.
    Mukherjee D; Roffi M
    Expert Opin Drug Metab Toxicol; 2007 Apr; 3(2):275-80. PubMed ID: 17428156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patients with non-ST-elevation acute coronary syndromes undergoing coronary artery bypass grafting in the modern era of antithrombotic therapy.
    Chew DP; Huang Z; Pieper KS; White H; Mahaffey KW; Ferguson JJ; Califf RM; Aylward PG
    Am Heart J; 2008 Feb; 155(2):239-44. PubMed ID: 18215592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FK419, a novel nonpeptide GPIIb/IIIa antagonist, restores microvascular patency and improves outcome in the guinea-pig middle cerebral artery thrombotic occlusion model: comparison with tirofiban.
    Moriguchi A; Maeda M; Mihara K; Aoki T; Matsuoka N; Mutoh S
    J Cereb Blood Flow Metab; 2005 Jan; 25(1):75-86. PubMed ID: 15678114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.